Pharmacokinetics and Pharmacodynamics of BI 135585 XX Administered as Oral Dose in Healthy Male Volunteers (Open-label, Single-dose Trial)
Phase of Trial: Phase I
Latest Information Update: 01 May 2016
At a glance
- Drugs BI 135585 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Aug 2012 New trial record
- 01 Jul 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.